Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-21
- Development stage
- Unknown
- Lead developer
- Curanter
- Administration
- Oral
01
Overview
CH-21 is a homeopathic remedy developed and marketed by Curanter Homeo, a retail company based in Patna, India. The product is available in oral formulations, including drops and tablets. As a homeopathic preparation, it is sold as a finished retail product rather than a drug candidate in a traditional pharmaceutical R&D pipeline. There is no publicly available clinical data, specific therapeutic indication, or defined pharmacological mechanism of action associated with this product on the developer's website. It is part of a series of commercial homeopathic products labeled CH-19 through CH-31.
- Brand names
- CH-21CH21CH 21
- Other names
- CH-21 dropsCH21 dropsCH 21 dropsCH-21 tabletsCH21 tabletsCH 21 tablets
Beyond the preview
Go deeper on CH-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-21.